Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
-
New HAE drug switch study aims for safer monthly shots
Disease control OngoingThis study checks if it's safe for people aged 12 and older with hereditary angioedema (HAE) to switch from their current preventive treatment to a new monthly injection called garadacimab. About 18 participants will receive garadacimab for around 3 months, and researchers will m…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 05:43 UTC
-
New hope for hemophilia: experimental clotting factor shows promise in chinese trial
Disease control OngoingThis study tests a new recombinant clotting factor (rVIII-SingleChain) in 60 Chinese males with severe hemophilia A. Participants receive the treatment 2-3 times weekly to prevent bleeding episodes. The goal is to see how well it works and if it is safe, including checking for si…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
New antibody shot study aims to help Immune-Compromised patients
Disease control OngoingThis study tests a medicine called IgPro20, which is given as a shot under the skin, in adults with primary immunodeficiency (PID) who have never received antibody therapy before. The goal is to see how the body processes the drug and whether it is safe. Only 8 people will take p…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for hemophilia b: Long-Lasting clotting factor under study
Disease control OngoingThis study tests a new drug called rIX-FP, which is a long-lasting clotting factor, in 23 Chinese men with hemophilia B. The goal is to see how well it prevents and treats bleeding episodes when given regularly. Participants receive the drug as a routine shot to keep their clotti…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 18, 2026 12:07 UTC